First-line dasatinib discontinuation in chronic myeloid leukaemia: another step towards an "operational cure"
Mené au Japon sur 68 patients atteints d'une leucémie myéloïde chronique récemment diagnostiquée et ayant reçu un traitement par dasatinib pendant au moins 24 mois avec une réponse moléculaire profonde soutenue, cet essai multicentrique de phase II évalue la survie sans rechute à 6 mois après l'arrêt du dasatinib (durée médiane de suivi : 23,3 mois)
Important advances have been made over the past decade in the management of patients with chronic myeloid leukaemia following the introduction of different tyrosine kinase inhibitors (TKIs). Discontinuation of treatment in patients with chronic myeloid leukaemia who have achieved a deep and sustained molecular response is an innovative cost-effective strategy aimed at reducing long-term toxicity. Several studies in which patients have been treated with imatinib, even if undermined by an extreme heterogeneity due to small and selected cohorts with different inclusion and relapse criteria, have shown that about 40% of patients maintain the response after therapy discontinuation and can reach an operational cure or treatment-free remission.